Sperm Cryopreservation for Male Cancer Patients: More than 10 Years of Experience, in Beijing China
Sperm Cryopreservation for Male Cancer Patients: More than 10 Years of Experience, in Beijing China
复制标题
DOI：
10.12659/msm.913513
复制
发表时间：
2019-05-03
影响因子：
3.1
通讯作者：
Gu, Yiqun
中科院分区：
文献类型：
--
作者：
Fu, Longlong;Zhou, Fang;Gu, Yiqun
背景：对男性癌症患者，尤其是青少年患者，保留生育能力是非常重要的。不幸的是，在中国男性癌症患者中，保留生育能力的使用率非常低。此外，冷冻精子的累计使用率也很低。材料/方法：我们通过收集2006年7月至2017年12月国家计划生育研究所人类精子库的现有信息，对中国的数据进行回顾性研究。结果：145例男性癌症患者接受了精子冷冻保存。患者年龄29.3±6.9岁，其中6.2%（9 / 145）为18岁以下的青少年。截至2018年6月，145名患者中只有9.7%（14人）返回使用其冷冻保存的精子进行辅助生殖技术（ART）。在33个ART周期中，51.5%（33个周期中有17个周期）的患者受孕，71.4%（14个周期中有10个周期）的患者怀孕。数据显示，患有睾丸癌或白血病的男性精子总数和进行性精子恢复率低于患有其他类型癌症的男性，而患有肉瘤的男性精子进行性最低。结论：医师应努力促进中国男性癌症患者保留生育能力。患有睾丸癌和白血病的患者需要额外的关注。
Background: Fertility preservation is very important for male cancer patients, especially adolescents. Unfortunately, the use of fertility preservation is very low among Chinese male cancer patients. Additionally, the cumulative rate of frozen sperm use is also low.Material/Methods: We performed a retrospective study by collecting available information at the Human Sperm Bank, National Research Institute for Family Planning from July 2006 to December 2017 to examine the data in China.Results: A total 145 male cancer patients underwent sperm cryopreservation. The patients were 29.3 +/- 6.9 years old, and 6.2% (9 out of 145) of the patients were adolescents under the age of 18 years old. As of June 2018, only 9.7% (14 out of 145) of patients returned to use their cryopreserved sperm for assisted reproduction technology (ART). Of the 33 ART cycles, conceptions were achieved in 51.5% (17 out of 33), and the rate of patients who had a baby was 71.4% (10 out of 14). The data indicate men with testicular cancer or leukemia had lower total sperm counts and recovery rate of progressive sperm than did men with other types of cancer, while men with sarcoma had the lowest progressive sperm.Conclusions: The physician should make an effort to promote fertility preservation for male cancer patients in China. And patients with testicular cancer and leukemia require additional attention.